Your browser doesn't support javascript.
loading
Prognostic significance of chronic kidney disease and impaired renal function in Japanese patients with COVID-19.
Tanaka, Hiromu; Chubachi, Shotaro; Asakura, Takanori; Namkoong, Ho; Azekawa, Shuhei; Otake, Shiro; Nakagawara, Kensuke; Fukushima, Takahiro; Lee, Ho; Watase, Mayuko; Sakurai, Kaori; Kusumoto, Tatsuya; Masaki, Katsunori; Kamata, Hirofumi; Ishii, Makoto; Hasegawa, Naoki; Okada, Yukinori; Koike, Ryuji; Kitagawa, Yuko; Kimura, Akinori; Imoto, Seiya; Miyano, Satoru; Ogawa, Seishi; Kanai, Takanori; Fukunaga, Koichi.
Afiliação
  • Tanaka H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
  • Chubachi S; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan. bachibachi472000@z6.keio.jp.
  • Asakura T; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan. takanori.asakura@gmail.com.
  • Namkoong H; Department of Clinical Medicine (Laboratory of Bioregulatory Medicine), Kitasato University School of Pharmacy, Tokyo, Japan. takanori.asakura@gmail.com.
  • Azekawa S; Department of Respiratory Medicine, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan. takanori.asakura@gmail.com.
  • Otake S; Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
  • Nakagawara K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
  • Fukushima T; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
  • Lee H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
  • Watase M; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
  • Sakurai K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
  • Kusumoto T; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
  • Masaki K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
  • Kamata H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
  • Ishii M; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
  • Hasegawa N; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
  • Okada Y; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.
  • Koike R; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Kitagawa Y; Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
  • Kimura A; Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan.
  • Imoto S; Department of Genome Informatics, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.
  • Miyano S; Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
  • Ogawa S; Health Science Research and Development Center (HeRD), Tokyo Medical and Dental University, Tokyo, Japan.
  • Kanai T; Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
  • Fukunaga K; Institute of Research, Tokyo Medical and Dental University, Tokyo, Japan.
BMC Infect Dis ; 24(1): 527, 2024 May 25.
Article em En | MEDLINE | ID: mdl-38796423
ABSTRACT

BACKGROUND:

Renal impairment is a predictor of coronavirus disease (COVID-19) severity. No studies have compared COVID-19 outcomes in patients with chronic kidney disease (CKD) and patients with impaired renal function without a prior diagnosis of CKD. This study aimed to identify the impact of pre-existing impaired renal function without CKD on COVID-19 outcomes.

METHODS:

This retrospective study included 3,637 patients with COVID-19 classified into three groups by CKD history and estimated glomerular filtration rate (eGFR) on referral Group 1 (n = 2,460), normal renal function without a CKD history; Group 2 (n = 905), impaired renal function without a CKD history; and Group 3 (n = 272), history of CKD. We compared the clinical characteristics of these groups and assessed the effect of CKD and impaired renal function on critical outcomes (requirement for respiratory support with high-flow oxygen devices, invasive mechanical ventilation, or extracorporeal membrane oxygen, and death during hospitalization) using multivariable logistic regression.

RESULTS:

The prevalence of comorbidities (hypertension, diabetes, and cardiovascular disease) and incidence of inflammatory responses (white blood counts, and C-reactive protein, procalcitonin, and D-dimer levels) and complications (bacterial infection and heart failure) were higher in Groups 2 and 3 than that in Group 1. The incidence of critical outcomes was 10.8%, 17.7%, and 26.8% in Groups 1, 2, and 3, respectively. The mortality rate and the rate of requiring IMV support was lowest in Group 1 and highest in Group 3. Compared with Group 1, the risk of critical outcomes was higher in Group 2 (adjusted odds ratio [aOR] 1.32, 95% confidence interval [CI] 1.03-1.70, P = 0.030) and Group 3 (aOR 1.94, 95% CI 1.36-2.78, P < 0.001). Additionally, the eGFR was significantly associated with critical outcomes in Groups 2 (odds ratio [OR] 2.89, 95% CI 1.64-4.98, P < 0.001) and 3 (OR 1.87, 95% CI 1.08-3.23, P = 0.025) only.

CONCLUSIONS:

Clinicians should consider pre-existing CKD and impaired renal function at the time of COVID-19 diagnosis for the management of COVID-19.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Renal Crônica / COVID-19 / Taxa de Filtração Glomerular Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Renal Crônica / COVID-19 / Taxa de Filtração Glomerular Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article